PECULIARITIES OF NEPHROPROTECTIVE EFFECT OF SULODEXIDE IN PATIENTS WITH DIABETIC NEPHROPATHY
Journal: Ukrainian Journal of Nephrology and Dialysis
Year: 2017

Introduction. Monocyte chemoattractant protein type 1 (MCP-1) and plasminogen activator inhibitor type 1 (PAI-1) play a key role in inflammation, fibrosis and progression of renal dysfunction. Sulodexide advantages in vascular pathology treatment were proved by clinical trials, however, its efficiency in diabetic nephropathy (DN) was investigated insufficiently.&#x0D; The aim of the present work – to study the influence of sulodexide on clinical and laboratory parametres, MCP-1 and PAI-1 levels